Catalyst Wire Dossier Catalyst Wire Dossier

Autologous CD34+ stem cells

CD34+ stem cells · Lisata Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Autologous CD34+ stem cells, covering 2017-02-15 to 2017-02-15. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina [Phase 3]

See pricing